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4 CIBMTR Best Abstract Awards for Clinical Researchof care for this patient population. Longer follow up is needed to
quantitate the impact of lower dose radiation on immune recovery,
risks of infection, cancer risk and other therapy-related late effects.6
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In the era of allelic typing and with bone marrow transplantation
(BMT) in CR1 restricted to patients at higher risk of treatment fail-
ure, it is important to evaluate whether BMT using alternative family
donors is equivalent to using an HLA-matched sibling donor (MSD)
or an unrelated donor (URD). We compared the outcomes of pa-
tients \18y reported to CIBMTR from 1993–2006 with AML,
ALL, CML and MDS undergoing a first allogeneic BMT. Donors
were MSD (N 5 1208), URD (N 5 266) or a mismatched related
donor (mmRD), either a 1 antigen mismatch at HLA-A, B or
DRB1 (N5 97) or phenotypically matched related donor (N5 54).
mmRD were typed by serological or DNA-based methods with all
results verified by lab report review. URD were all 8/8 allelic matches
at HLA-A,B,C,DRB1 through the NMDP retrospective typingprogram. All patients received myeloablative conditioning, T-cell
replete bone marrow grafts and calcineurin inhibitor-based GVHD
prophylaxis. Recipients of URD had more intermediate/advanced
disease (p\0.01), were transplanted later after diagnosis (p\0.01)
and more received TBI (p\0.01). There were no significant differ-
ences (p\0.01) between the phenotypically matched and 1-Ag mis-
matched related donor groups, so they were combined in the final
multivariate model (as mmRD). Recipients of MSD had less acute
GVHD grades 3–4, chronic GVHD, 100-day mortality, TRM and
overall mortality (OM) as well as increased DFS compared with
both the URD and mmRD groups (Table). Relapse rates were
similar for all groups. Comparisons between the mmRD and URD
groups did not detect a difference in acute GVHD grades 3–4,
chronic GVHD, TRM, 100-day mortality, OM, DFS and relapse
(Table). In this large cohort of paediatric patients, MSD have supe-
rior outcomes to either mmRD or URD. An 8/8 allelic matched
URD results in outcome similar to mmRD. A family donor is an ac-
ceptable alternative to an allelic matched URD, but does not result in
the same outcome as a MSD.
Pairwise comparisons of mmRD vs. MSD and URD vs. mmRD
mmRD vs. MSD URD vs. mmRD
Outcome OR/RR* (95%CI), p OR/RR* (95%CI), p100-day mortality 2.54 (1.55-4.17),\0.01 0.95 (0.54-1.66), 0.85
Overall mortality 1.48 (1.12-1.97),\0.01 0.98 (0.72-1.33), 0.87
Disease-free survival 1.38 (1.09-1.75), 0.01 1.02 (0.77-1.35), 0.90
TRM 3.01 (2.10-4.33),\0.01 1.16 (0.77-1.64), 0.74
Relapse 0.90 (0.65-1.24), 0.52 1.09 (0.74-1.60), 0.66
Acute GVHD III-IV 3.41 (2.38-4.89),\0.01 0.75 (0.49-1.14), 0.18
Chronic GVHD 3.09 (2.24-4.27),\0.01 1.27 (0.88-1.82), 0.20*OR for 100-day mortality. RR for all other outcomes.
